[Skip to Content]

Upstate Active Clinical Trials

Study Title:

ANBL1531 - A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)

What is the purpose of the study? (in Layman's terms, please describe the study)

Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)

Upstate Institutional Review Board (IRB) Number:

1601784

Study/Protocol ID:

ANBL1531

Study Phase:

III

Patient Age Group:

Children

Principal Investigator:

Melanie A Comito

Who is eligible?

Patient must be ≥ 365 days and ≤ 30 years of age at diagnosis.

What is involved if I participate?

  • How long is the study?
    until accrual is met
  • Is transportation provided or reimbursed?
    No
  • Is parking provided or reimbursed?
    Yes
  • What tests and procedures are involved?
    surgery, transplant, blood draws, imaging, radiation therapy

Where will the study take place?

SUNY Upstate Medical University

Other Information:

N/A

Who can I contact for more information?

Name: Karen B Bilynsky
Phone: 315-464-7601
Email: [email protected]

Return to Previous Page || Search Again

Top